AR040450A1 - Formulacion superfina de salmeterol - Google Patents
Formulacion superfina de salmeterolInfo
- Publication number
- AR040450A1 AR040450A1 AR20030102220A ARP030102220A AR040450A1 AR 040450 A1 AR040450 A1 AR 040450A1 AR 20030102220 A AR20030102220 A AR 20030102220A AR P030102220 A ARP030102220 A AR P030102220A AR 040450 A1 AR040450 A1 AR 040450A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- salmeterol
- refers
- metered dose
- propellant
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004017 salmeterol Drugs 0.000 title abstract 3
- 239000003380 propellant Substances 0.000 abstract 3
- 239000006184 cosolvent Substances 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 239000008249 pharmaceutical aerosol Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulación farmacéutica para utilizar en la administración por inhalación de un agonista beta 2 de acción prolongada. En particular, la presente se refiere a una formulación de salmeterol en solución de HFA altamente eficiente, químicamente estable, para administrar utilizando inhaladores dosificadores presurizados (pMDIs) que se caracterizan por una profunda penetración pulmonar. La presente también se refiere a métodos para la preparación de dicha formulación y a su uso en enfermedades respiratorias como por ejemplo asma y enfermedad obstructiva pulmonar crónica (COPD). Reivindicación 1: Una formulación farmacéutica en aerosol que puede administrarse por medio de inhaladores dosificadores presurizados Caracterizada porque comprende un ingrediente activo que se selecciona entre salmeterol o un estereoisómero, sal aceptable para uso fisiológico o solvato del mismo, disuelto en un sistema propelente, donde dicho sistema propelente consiste en un propelente HFA licuado, un co-solvente y entre 0 y 5% p/p de agua, y la cantidad del cosolvente no es más del 35% p/p del peso total de la formulación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02023589A EP1415647A1 (en) | 2002-10-23 | 2002-10-23 | "Long-acting beta-2 agonists ultrafine formulations" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040450A1 true AR040450A1 (es) | 2005-04-06 |
Family
ID=32087950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102220A AR040450A1 (es) | 2002-10-23 | 2003-06-20 | Formulacion superfina de salmeterol |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8088362B2 (es) |
| EP (2) | EP1415647A1 (es) |
| AR (1) | AR040450A1 (es) |
| AT (1) | ATE421875T1 (es) |
| AU (1) | AU2003245965A1 (es) |
| BR (1) | BR0306663A (es) |
| CA (1) | CA2503183C (es) |
| DE (1) | DE60326053D1 (es) |
| ES (1) | ES2319887T3 (es) |
| NO (1) | NO20051956L (es) |
| PE (1) | PE20040314A1 (es) |
| WO (1) | WO2004037227A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| DZ2947A1 (fr) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
| IT1317720B1 (it) * | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| IT1318514B1 (it) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| ES2222294T3 (es) * | 2001-07-02 | 2005-02-01 | Chiesi Farmaceutici S.P.A. | Formulacion optimizada de tobramicina para administracion en forma de aerosol. |
| EP1415647A1 (en) | 2002-10-23 | 2004-05-06 | CHIESI FARMACEUTICI S.p.A. | "Long-acting beta-2 agonists ultrafine formulations" |
| EP1595531A1 (en) * | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| WO2008057248A2 (en) * | 2006-10-26 | 2008-05-15 | Next Breath Llc | Phospholipid-based inhalation system |
| EP3311820A1 (en) * | 2008-02-26 | 2018-04-25 | Sunovion Respiratory Development Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| US20100055045A1 (en) * | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2440196A4 (en) * | 2009-06-09 | 2013-01-02 | Elevation Pharmaceuticals Inc | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC |
| WO2012007729A2 (en) * | 2010-07-16 | 2012-01-19 | Cipla Limited | Pharmaceutical compositions |
| US20230271770A1 (en) * | 2020-04-21 | 2023-08-31 | Amphastar Pharmaceuticals, Inc. | Anti-Viral Pharmaceutical Formulations Administered Via Devices for Lung Targeted Delivery |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
| CA2206782C (en) * | 1994-12-22 | 2007-04-03 | Astra Aktiebolag | Aerosol drug formulations |
| EP1769819A3 (en) * | 1995-04-14 | 2013-05-22 | GlaxoSmithKline LLC | Metered dose inhaler for fluticasone propionate |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| US6423298B2 (en) * | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| ATE283033T1 (de) * | 1998-07-24 | 2004-12-15 | Jago Res Ag | Medizinische aerosolformulierungen |
| IT1303788B1 (it) | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| US7074388B2 (en) * | 1998-12-10 | 2006-07-11 | Kos Life Science, Inc. | Water stabilized medicinal aerosol formulation |
| US20050048001A1 (en) * | 1999-11-23 | 2005-03-03 | Cripps Alan Leslie | Pharmaceutical formulations of salmeterol |
| DE60019167T2 (de) * | 1999-12-24 | 2006-05-11 | Glaxo Group Ltd., Greenford | Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason |
| IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| GB0009773D0 (en) * | 2000-04-19 | 2000-06-07 | Univ Cardiff | Particulate composition |
| IT1318514B1 (it) | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
| UA73986C2 (uk) | 2000-05-22 | 2005-10-17 | К'Єзі Фармачеутічі С.П.А. | АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ |
| SE0004750D0 (sv) * | 2000-12-19 | 2000-12-19 | Astrazeneca Ab | Novel formulation |
| US20020189610A1 (en) * | 2001-02-01 | 2002-12-19 | Karl-Heinz Bozung | Pharmaceutical compositions containing an ipratropium salt and a betamimetic |
| US6455028B1 (en) * | 2001-04-23 | 2002-09-24 | Pharmascience | Ipratropium formulation for pulmonary inhalation |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| SI3494995T1 (sl) | 2002-03-01 | 2020-08-31 | Chiesi Farmaceutici S.P.A. | Superfina formulacija formoterola |
| EP1415647A1 (en) | 2002-10-23 | 2004-05-06 | CHIESI FARMACEUTICI S.p.A. | "Long-acting beta-2 agonists ultrafine formulations" |
| EP1340492A1 (en) | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
| EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
-
2002
- 2002-10-23 EP EP02023589A patent/EP1415647A1/en not_active Withdrawn
-
2003
- 2003-06-18 WO PCT/EP2003/006444 patent/WO2004037227A1/en not_active Application Discontinuation
- 2003-06-18 CA CA2503183A patent/CA2503183C/en not_active Expired - Fee Related
- 2003-06-18 DE DE60326053T patent/DE60326053D1/de not_active Expired - Lifetime
- 2003-06-18 EP EP03738060A patent/EP1553922B1/en not_active Revoked
- 2003-06-18 AT AT03738060T patent/ATE421875T1/de not_active IP Right Cessation
- 2003-06-18 US US10/531,867 patent/US8088362B2/en not_active Expired - Fee Related
- 2003-06-18 ES ES03738060T patent/ES2319887T3/es not_active Expired - Lifetime
- 2003-06-18 BR BR0306663-0A patent/BR0306663A/pt not_active Application Discontinuation
- 2003-06-18 AU AU2003245965A patent/AU2003245965A1/en not_active Abandoned
- 2003-06-20 AR AR20030102220A patent/AR040450A1/es not_active Application Discontinuation
- 2003-06-20 PE PE2003000624A patent/PE20040314A1/es not_active Application Discontinuation
-
2005
- 2005-04-21 NO NO20051956A patent/NO20051956L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20040314A1 (es) | 2004-07-05 |
| BR0306663A (pt) | 2004-10-19 |
| ES2319887T3 (es) | 2009-05-14 |
| US20060120966A1 (en) | 2006-06-08 |
| EP1415647A1 (en) | 2004-05-06 |
| DE60326053D1 (de) | 2009-03-19 |
| CA2503183A1 (en) | 2004-05-06 |
| NO20051956D0 (no) | 2005-04-21 |
| CA2503183C (en) | 2011-06-14 |
| US8088362B2 (en) | 2012-01-03 |
| AU2003245965A1 (en) | 2004-05-13 |
| EP1553922B1 (en) | 2009-01-28 |
| NO20051956L (no) | 2005-07-22 |
| WO2004037227A1 (en) | 2004-05-06 |
| EP1553922A1 (en) | 2005-07-20 |
| ATE421875T1 (de) | 2009-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101593A2 (es) | Formulación superfina de formoterol | |
| AR038641A1 (es) | Formulacion superfina de formoterol | |
| AR040450A1 (es) | Formulacion superfina de salmeterol | |
| ES2314408T3 (es) | Formulaciones de hfc en solucion que contienen un anticolinergico. | |
| ME02342B (me) | Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom | |
| ES2391563T5 (es) | Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor | |
| PE20160853A1 (es) | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) | |
| KR101629119B1 (ko) | 티오트로피움 함유 조성물을 포함하는 흡입기 | |
| ATE308317T1 (de) | Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung | |
| WO2000047203A9 (en) | Formulation and system for intra-oral delivery of pharmaceutical agents | |
| AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
| RU2013104401A (ru) | Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы | |
| PE20070353A1 (es) | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol | |
| DK2089008T3 (da) | Formulationer til afgivelse via tryksatte, afmålte dosisinhalatorer omfattende en essentiel olie som suspensionsstabilisator | |
| PE20011271A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
| EP2934544B1 (en) | Pharmaceutical formulation comprising ciclesonide | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| ES2533535T3 (es) | Soluciones para inhalación | |
| AR078494A1 (es) | Formulaciones farmaceuticas en aerosol de formoterol y dipropionato de beclometasona | |
| AR038764A1 (es) | Formulacion de una solucion de inhalacion con una sal de tiotropio | |
| WO2004103339A3 (en) | Improved metered dose inhaler | |
| MX2024006942A (es) | Composicion farmaceutica que comprende salbutamol. | |
| TH66681A (th) | สูตรผสมที่ละเอียดเป็นพิเศษของฟอร์มอเทอรอล |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |